Corporate Overview

Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. We combine our proven scientific expertise and depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our programs are focused on the implementation of novel pharmacological approaches to control cell death. Our proprietary drug candidates act via unique mechanisms and targets to kill cancer and protect healthy cells.

Investor Presentations



Upcoming Events

Recent Events

Recent Releases

Annual Report

Investor Relations

Rachel Levine
Vice President, Investor Relations
Cleveland BioLabs, Inc.
Phone: +1  (917) 375-2935
Fax: +1 (716) 849-6820
E-mail: rlevine@cbiolabs.com

Management Team

Yakov Kogan, Ph.D., MBA
Chief Executive Officer

Andrei Gudkov, Ph.D., D. Sci.
Chief Scientific Officer

C. Neil Lyons, CPA
Executive Vice President, Chief Financial Officer

Ann Hards, Ph.D.
Executive Vice President Regulatory Affairs

Michelle Ross, DVM, MS, Ph.D.
Senior Vice President, Public Health and Government Affairs

Leah Brownlee, J.D.
Vice President, Compliance and Operations/Corporate Secretary

Anna Muchnik, MS
Senior Vice President Pharmaceutical Development

Andrei Purmal, Ph.D.
Vice President, Chemistry

Transfer Agent

Continental Stock Transfer & Trust Company 
17 Battery Place
8th Floor
New York, NY 10004
Tel: (212) 509-4000
Fax: (212) 509-5150

Auditors

Meaden & Moore, Ltd.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue